Business Of Biotech
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.
- Update frequency
- every 7 days
- Average duration
- 49 minutes
- Episodes
- 270
- Years Active
- 2020 - 2025
Biopolitics With Allan Shaw
We love to hear from our listeners. Send us a message.
The notion that political influence has no place in biology appears poised for a test it hasn’t studied for. Trump administration nominations, f…
T-Cells For The Win With Adaptimmune's Adrian Rawcliffe
We love to hear from our listeners. Send us a message.
In August of this year, the first TCR cell therapy to be approved for use in the U.S. was greenlighted by the FDA for patients with unresectable…
Serving The Underserved With Gates MRI's Claire Wagner, M.D.
We love to hear from our listeners. Send us a message.
On this episode of the Business of Biotech, Bill and Melinda Gates Medical Research Institute's (Gates MRI) Dr. Claire Wagner joins us to share …
An Unanticipated Biotech Startup With OS Therapies' Paul Romness
We love to hear from our listeners. Send us a message.
Becoming a biotech CEO wasn't on Paul Romness' bingo card. He'd forged his place in the biopharma industry as a foremost public and policy affai…
Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright
We love to hear from our listeners. Send us a message.
It might just be coincidence, but it sure seems like Bill Enright has a knack for making big moves at inopportune times, then turning the expect…
Obesity Tx End-Around With Skye Bioscience's Punit Dhillon
We love to hear from our listeners. Send us a message.
While the trend toward CB1 inhibition for obesity took a small hit with the release of Novo Nordisk's small molecule oral cannabinoid receptor (…
Biotech C-Suite Construction With Allan Shaw
We love to hear from our listeners. Send us a message.
Allan Shaw is back with us this week to dig into the complexities of strategic hiring in biotech. We cover strategies for the step-wise assembly…
The Peptide Promise With NervGen's Mike Kelly
We love to hear from our listeners. Send us a message.
Mike Kelly faced a self-reckoning before he took the job as CEO at NervGen, a company developing peptide therapeutics targeted specifically at c…
Biotech Course Correction With Treehill Partners' Ali Pashazadeh
We love to hear from our listeners. Send us a message.
It wouldn't be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spread…
An AI Awakening With Profluent Bio's Hilary Eaton, Ph.D.
We love to hear from our listeners. Send us a message.
Hilary Eaton, Ph.D. was a self-described AI skeptic, particularly as it relates to using the tool in drug discovery. Then, a series of professio…
Picking Biotech Jockeys With SR One's Simeon George, M.D.
We love to hear from our listeners. Send us a message.
SR One Capital Management CEO Simeon George, M.D. has a seemingly innate ability to pick winning biotech builders. Early on, he and his firm got…
Embracing Biotech Chaos With Memo's Erik van den Berg
We love to hear from our listeners. Send us a message.
Erik van den Berg is CEO and board member at Memo Therapeutics, and he's a student of biotech chaos. In fact, he's been embracing it with intent…
Pivoting To RNA With Circio's Dr. Erik Digman Wiklund
We love to hear from our listeners. Send us a message.
This week, it’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO Erik Digman Wiklund, Ph.D. and guest co-host Anna R…
mRNA Upstarts With Radar Therapeutics' Sophia Lugo and Eerik Kaseniit, Ph.D.
We love to hear from our listeners. Send us a message.
Guest co-host Anna Rose Welch of Advancing RNA fame joins us on this week’s Business of Biotech podcast for a conversation with the leaders of R…
Steering Through Setbacks with AVEO Oncology's Michael Bailey
We love to hear from our listeners. Send us a message.
For all the drug commercialization successes he's played a leading hand in during his tenures at GSK, Genentech, and ImClone—Androderm, Augmenti…
Leading From Within with ISCT & Kiji's Miguel Forte, M.D.
We love to hear from our listeners. Send us a message.
He's been a big pharma executive. He's a multi-time biotech founder and current biotech CEO. He was once a regulator. He's a physician. He serve…
The Allogeneic Future with Poseida's Kristin Yarema, Ph.D.
We love to hear from our listeners. Send us a message.
Kristin Yarema, Ph.D. thinks the progress of CAR T therapeutics is allogeneic. In fact, she says CAR T-cell therapies have to become a one-to-ma…
Expanding The Proteome with ProFound's John Lepore, M.D.
We love to hear from our listeners. Send us a message.
Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big. It began with a simple question: What if more RN…
From The Bench To The Boardroom with ImmunityBio's Enrique Diloné
We love to hear from our listeners. Send us a message.
While organic chemistry lectures caused many of his peers at NYU to wring their hands, gnash their teeth, and question life choices, then-19-yea…
First AI Antibody In Humans with Aulos' Aron Knickerbocker
We love to hear from our listeners. Send us a message.
Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. On this week's episode of the Business of Bi…